Cytokinetics Inc. has patented ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 (CD38) inhibitors reported to be useful for the treatment of cancer, obesity and cardiovascular, inflammatory, metabolic, muscle, neurological and renal disorders, among others.